Table 3.
Therapies given upon disease progression (eight patients were receiving study treatment at data collection. Information was unavailable for ten patients)
| Therapy (n) | Second-line therapy | All lines of treatment |
|---|---|---|
| Platinum doublet | 46 | 60 |
| Without bevacizumab | 31 | 41 |
| With bevacizumab | 15 | 21 |
| EGFR TKI | 30 | 35 |
| Erlotinib | 21 | 25 |
| Gefitinib | 8 | 14 |
| Erlotinib + tivantinib | 1 | 1 |
| Erlotinib + pemetrexed | 0 | 1 |
| Gefitinib + pemetrexed | 0 | 1 |
| Single-agent chemotherapy | 7 | 39 |
| Docetaxel + bevacizumab | 3 | 4 |
| Pemetrexed | 3 | 15 |
| Docetaxel | 1 | 24 |
| Pemetrexed + bevacizumab | 0 | 1 |
| Platinum doublet + EGFR TKI | 1 | 2 |
| With erlotinib | 1 | 2 |
| Others | 0 | 16 |
EGFR TKI epidermal growth factor receptor tyrosine kinase inhibitor